gelatinase-associated lipocalin, interleukin-18, and liver fatty acid binding protein to predict acute kidney injury and prolonged acute kidney injury. Design: Prospective observational pilot cohort study. Setting: Four Canadian tertiary healthcare PICUs. Patients: Eighty-one children 1 month to 18 years old. Exclusion criteria were as follows: cardiac surgery, baseline severe kidney disease, and inadequate urine or serum for PICU days 1-3. Interventions: PICUs performed standardized urine collection protocol to obtain early PICU admission urine samples, with deferred consent. Measurements and Main Results: Study barriers and facilitators were recorded. Acute kidney injury was defined based on Kidney Disease: Improving Global Outcomes serum creatinine criteria (acute kidney injury serum creatinine ) and by serum creatinine and urine output criteria (acute kidney injury serum creatinine+urine output ) Prolonged acute kidney injury was defined as acute kidney injury duration of 48 hours or more. PICU days 1-3 neutrophil gelatinase-associated lipocalin, interleukin-18, and liver fatty acid binding protein were evaluated for acute kidney injury prediction (area under the curve). Biomarkers on the first day of acute kidney injury attainment (day 1 acute kidney injury) were evaluated for predicting prolonged acute kidney injury. Eighty-two to 95% of subjects had urine collected from PICU days 1-3. Acute kidney injury serum creatinine developed in 16 subjects (20%); acute kidney injury serum creatinine+urine output developed in 38 (47%). On PICU day 1, interleukin-18 predicted acute kidney injury serum creatinine with area under the curve=0.82, but neutrophil gelatinase-associated lipocalin and liver fatty acid binding protein predicted acute kidney injury serum creatinine with area under the curve of less than or equal to 0.69; on PICU day 2, area under the curve was higher (not shown). Interleukin-18 and liver fatty acid binding protein on day 1 acute kidney injury predicted prolonged acute kidney injury serum creatinine (area under the curve=0.74 and 0.83, respectively). When acute kidney injury serum creatinine+urine output was used to define acute kidney injury, biomarker area under the curves were globally lower.
A cute kidney injury (AKI) occurs in 10-20% of patients in the PICU (1, 2) . AKI often develops early in PICU admission and is consistently reported to be a risk factor for prolonged ventilation, longer hospital stay, and increased PICU mortality (1) (2) (3) (4) .
AKI definition utilizes serum creatinine (SCr) rise from baseline or urine output (UO) decrease, per the international Kidney Disease: Improving Global Outcomes (KDIGO) definition (5) . However, SCr rise with AKI is delayed, resulting in late diagnosis, treatment, and prevention of AKI complications (6) . Several treatments may attenuate renal tissue injury (7-10) but have been understudied or unsuccessful in humans, at least partially due to the shortcoming of SCr to promptly detect AKI (6, 11) .
Several early AKI biomarkers have been studied in cardiac surgery patients (12) (13) (14) and less so in noncardiac surgery patients (15) (16) (17) . Most are urine proteins upregulated in renal tubule cells with cell (or tissue) injury, as opposed to SCr that rises due to renal function change. Thus, biomarkers have been referred to as "structural" AKI biomarkers (14, 18) . New AKI biomarkers may rise before functional impairment becomes evident or serve as measures of AKI severity. Neutrophil gelatinase-associated lipocalin (NGAL) is extruded into urine with AKI, involved in injury and repair of renal tubule cells (19) . Other recently studied AKI biomarkers include interleukin-18 (IL-18) that plays a role in activating macrophages, T-cell immunity and mediating ischemic tubule injury (20) , and liver-type fatty acid binding protein (LFABP), a proximal tubule cytoplasmic fatty acid carrier that binds intermediates of peroxidation (21) . These biomarkers have shown promise for early AKI diagnosis in children undergoing cardiac surgery or single-center studies of noncardiac populations (12, 13, 15-17, 22, 23) . Few AKI biomarker studies have been published in the noncardiac surgery PICU population, and no multicentre PICU biomarker studies have been published. This research gap may be contributed to by the fact that recruiting such patients into early AKI diagnostic biomarker studies is difficult. Because AKI occurs early in PICU admission (1, 2) , recruiting patients early enough in PICU admission to collect urine specimens for biomarker measurement is challenging.
There is also a knowledge gap regarding the impact of UO criteria of AKI definition, on AKI biomarker performance. Almost all AKI biomarker studies have only applied the KDIGO SCr criteria to define AKI, ignoring UO criteria. AKI ascertainment may differ substantially when SCr criteria alone are used versus applying both SCr and UO criteria to define AKI (3, 24) . The extent to which applying UO criteria in AKI definition affects AKI biomarker diagnostic performance is unknown.
We hypothesized that urine NGAL, IL-18, and LFABP are early diagnostic markers of AKI and predict prolonged AKI duration (as a marker of AKI severity), in noncardiac surgery children admitted to the PICU and that inclusion of UO criteria to define AKI modifies biomarker diagnostic performance. We also hypothesized that instituting a PICU clinical urine collection protocol would reduce the challenge of studying of early AKI biomarkers. We performed a pilot multicenter study to evaluate feasibility of a urine collection protocol on all children admitted to PICU for procurement of early AKI biomarkers. We used this opportunity to evaluate and compare urine NGAL, IL-18, LFABP for early diagnosis of AKI defined using SCr criteria and AKI defined using both SCr and UO criteria. ; immediately postrenal transplantation or cardiac surgery; admitted with a primary renal disease (e.g., nephritis); admitted to PICU for less than 2 calendar days. Enrollement occurred at the latest by PICU day 3. Research ethics board approval was obtained to perform research activities at all institutions.
MATERIALS AND METHODS

Design and Setting
Recruitment
The subject eligibility evaluation procedure is shown in Supplemental Figure 1 (Supplemental Digital Content 1, http://links. lww.com/PCC/A441; legend, Supplemental Digital Content 3, http://links.lww.com/PCC/A443). To maximize multicenter staff participation and encourage recruitment, we performed a 2-to 4-week nurse and physician prestudy education phase (e-mails, in-services, and study posters), informing on the study rationale and protocol. Following this, a PICU urine collection protocol was instituted. This protocol included urine collection daily (from existing urinary catheters, urine collection bag, or cotton balls in children wearing diapers) for the first 3 PICU days on "all" PICU patients. Urine samples were not used for study purposes until the patient was recruited (deferred consent) (25) , but were placed in a 4°C fridge within the PICU until the patient was screened for eligibility. Every 1-3 days, the research team performed eligibility screening (inclusion and exclusion criteria) for all PICU patients. Eligible patients were screened for urine specimen number adequacy and measures of SCr. Of eligible patients (as per criteria Pediatric Critical Care Medicine www.pccmjournal.org e237 described above), only those with 1) greater than or equal to 1 urine specimen if admitted for 2 days or greater than or equal to 2 urine specimens if admitted for 3 days and 2) greater than or equal to 1 SCr measurement if admitted for 2 days or greater than or equal to 2 SCr measurements if admitted for 3 calendar days or more were considered for recruitment. Patients fulfilling clinical and specimen eligibility criteria were approached for informed consent and/or patient assent (if appropriate). Urine from patients not eligible or refusing participation was immediately discarded.
Study Procedure and Clinical Data Collection
The study occurred over 6-10 weeks at each site. Once a patient was recruited (at the latest PICU day 3), daily urine collection continued for up to 5 days from PICU admission. Urine specimens were centrifuged (1,000g, 15 min, 21°C), aliquoted and stored at -80°C until biomarker measurement. Urine specimens remained in the 4°C fridge for 72 hours or less. Prior studies suggest that biomarkers are stable under similar conditions (26) .
Clinical data were collected for up to 14 days of PICU admission on case report forms with a detailed instructions manual to ensure cross-site data consistency. The central site coordinator performed training for each site coordinator at study initiation, followed by regular phone and email contact throughout study. Clinical variables included age, gender, weight, height, past medical history, primary PICU diagnosis, fluid balance, sepsis or infection (defined by a positive body fluid culture or infection diagnosis [sepsis, pneumonia, and meningitis] in admission or discharge summaries), death, mechanical ventilation, extracorporeal membrane oxygenation, dialysis, available variables for the Pediatric Risk of Mortality II (PRISM) score (which does not include a renal component) (27) , and medications including vasopressors, selected nephrotoxins (including nonsteroidal anti-inflammatory agents, vancomycin, aminoglycosides, acyclovir/ganciclovir derivatives, and amphotericin), and diuretics. UO at every 8-hour interval was recorded (to apply the AKI definition described below) for up to 7 PICU days. Our previously performed single-center study (28) informed us that UO is very poorly recorded in most patients admitted for over 7 days. Routinely collected SCr values were recorded. When SCr was not measured by the clinical team, if leftover serum from other tests performed that day was available in the hospital laboratory, we obtained this serum to measure SCr when feasible. Data were entered into a secure REDCap database, cleaned every 1-2 months, with 10% data re-entry to capture errors and sites were queried for missing or unclear data.
Baseline SCr was defined as the lowest SCr within 3 months before PICU admission (5). When baseline SCr was not available, baseline eGFR of 120 mL/min/1.73 m 2 was assumed and baseline SCr was estimated by back-calculating from the Chronic Kidney Disease in Children eGFR formula and height (29) . When no height or baseline SCr were available, eGFR was estimated using a height-independent eGFR equation derived in Europe and validated in Canada (30, 31) , with back-calculation of SCr to estimate baseline SCr.
Throughout the study, sites systematically recorded barriers and facilitators to recruitment, specimen, and data collection feasibility.
Laboratory Measurements
SCr measurements were performed at each site's central laboratory, to maintain within-subject assay consistency for evaluating SCr change from baseline. All sites report IDMS-traceable SCr. Frozen urine was shipped to the Montreal at the end of the study period and stored at -80°C. Biomarkers were measured at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory, OH. NGAL was measured using a commercial ELISA kit (Bioporto, Gentofte, Denmark). LFABP was measured using a microbead-based assay (MesoScale Discovery [MSD], Gaithersburg, MD) on a luminex system detected by a Sector Imager 2400 (MSD). IL-18 was measured using an IL-18 ELISA kit (Medical & Biological Laboratories, Nagoya, Japan). Verified inter-and intraassay biomarker assay coefficient of variations were less than or equal to 10%. Biomarkers were measured in duplicate and corrected for urine creatinine. Personnel measuring biomarkers were blinded to clinical outcomes.
Outcomes
The primary study feasibility outcome was achieving urine collection on days 1, 2, and 3 of PICU admission. The primary outcome for biomarker analyses was AKI based on the KDIGO definition (5). Because few AKI biomarker studies have used the UO criteria to define AKI, and few pediatric studies have evaluated the UO criteria for associations with clinical outcomes (24), we defined AKI in two ways. The first was to only apply KDIGO SCr criteria (hereafter, AKI SCr ). Peak SCr during PICU admission was divided by baseline SCr to calculate percentage SCr rise. Subjects with SCr rise greater than or equal to 50% or greater than or equal to 26.5 μmol/L from baseline were classified as AKI SCr stage 1; subjects with SCr doubling were classified as stage 2; those with SCr tripling, requiring dialysis or eGFR less than 35 mL/min/1.73 m 2 were classified as stage 3. We also defined AKI using both SCr and UO criteria for AKI definition, whereby a patient may be classified as having AKI if they either fulfill SCr criteria (described above) or UO criteria. The UO criteria were stage 1 AKI if UO was less than 0.5 mL/kg/hr for 8 hours, stage 2 if UO was less than 0.5 mL/kg/ hr for 16 hours, or stage 3 if the patient was anuric for 12 hours or had UO less than 0.3 mL/kg/hr for 24 hours. When evaluating consecutive 8-hour intervals, we performed this in a contiguous manner for different PICU days (e.g., evaluating the last 8 hr of the prior day and the first 8 hr of the current day to determine that 16-hour UO severity stratum). Of note, the KDIGO guideline defines UO AKI in adults using 6-hour, rather than 8-hour intervals. However, almost all published pediatric AKI studies have defined AKI using the 8-hour intervals used in this study, from the original published pediatric AKI modified definition (3, 24) . For consistency with past research, we utilized these pediatric-specific UO criteria, referring to the combined SCr or UO-based definition as AKI SCr+UO , (or "complete" KDIGO AKI definition).
A secondary biomarker outcome was prolonged AKI duration, defined as AKI criteria fulfillment for 48 hours or more from the day of first evidence of AKI (e.g., the first day that SCr rises by at least 50%) (3).
Statistical Analysis
Continuous variables were compared between groups using t tests, one-way analysis of variance, Mann-Whitney U or KruskalWallis tests. Categorical variables were compared using Fisher AKI SCr = acute kidney injury defined using serum creatinine criteria, AKI SCr+UO = acute kidney injury defined using both serum creatinine or urine output criteria. a exact or chi-square tests. The multicenter recruitment goal was 15-20 patients per site within 4-6 weeks. Analyses were performed using STATA version 10 (College Station, TX). Analyses were performed separately using AKI SCr and AKI SCr+UO definitions.
Biomarkers for Early AKI Diagnosis
Biomarker concentrations on PICU days 1 to 3 were plotted and compared between AKI and non-AKI groups, in subjects with biomarkers available from all 3 days. Calculation of area under the receiver operating characteristic curve (AUC, 95% CI) was used to evaluate biomarkers from PICU days 1-3 (in patients with biomarkers available on those individual days), to predict AKI development. All non-AKI subjects with biomarkers available were included in this AUC calculation; only AKI subjects who had not yet developed AKI by the day of assessment were included in these analyses.
Biomarker Associations With Prolonged AKI
In AKI subjects, biomarkers measured on the first day of AKI attainment were evaluated for predicting prolonged AKI duration using AUC analysis.
RESULTS
Study Population
Our final cohort included 81 children (Fig. 1, study flow) . AKI SCr developed in 16 subjects (20%) (stage 1, n = 11; stage 2 or worse, n = 5); AKI SCr+UO developed in 38 subjects (47%) (stage 1, n = 25; stage 2 or worse, n = 13). Baseline SCr was available in 37 patients (46%). About 95% of all AKI developed by PICU day 4. There was 73% agreement between AKI SCr and AKI SCr+UO designations (κ statistic = 0.44; Supplemental Table 1 , Supplemental Digital Content 2, http://links.lww.com/ PCC/A442, shows AKI staging severity by each definition). Primary reasons for PICU admission were respiratory (n = 21; 26%), neurosurgical (n = 15; 19%), orthopedic or trauma (n = 14; 17%), hematologic-oncologic (n = 6; 7%), or other (n = 25; 31%), with no significant difference between AKI and non-AKI groups (not shown). In general, differences in patient characteristics between AKI versus non-AKI groups were more striking, with increased illness severity markers (i.e., higher PRISM, more vasopressor use, longer stay; Table 1 ) when AKI was defined by SCr criteria, compared with defining AKI by SCr or UO criteria (Table 1) .
PICU Urine Collection Protocol/Study Feasibility
Sites easily attained recruitment goals (Fig. 1) . Study barriers and facilitators were identified from discussions with PICU staff, coordinators, and investigators ( Table 2) . In general, barriers were related to intersite differences in data availability, care processes, impeding on protocol adherence. These were mostly resolvable by intersite regular communication, clarifying instructions. Study facilitators were mainly related to open, consistent communication between study and clinical staff and considering site-specific processes during protocol development. Figure 1 displays that the urine collection protocol resulted in a urine specimen available 82%, 95%, and 83% of subjects on PICU days 1, 2, and 3, respectively. Sixty-seven percent of subjects had urine specimens available all 3 days. There was no significant difference in protocol urine collection between AKI SCr and non-AKI SCr subjects (2.3 ± 0.7 vs 2.6 ± 0.5 urines within the first 3 PICU days, respectively) nor between AKI SCr+UO and AKI SCr+UO subjects (2.5 vs 2.7 urine samples, respectively).
Involving head nurse in planning
Re: study initiation and maintenance Nurses more aware, reminded of urine protocol. Head nurses is research team member or involved in designing sitespecific study feasibility methods RA/site investigator PICU presence Having one study RA puts a face to the study; helped remind staff of study Prefer consistent RA over "hospital research service, " unless research service has constant presence Deferred consent, during/after PICUwide urine protocol collection At recruitment, urine often available from the first 2-3 PICU days; i.e., protocol successful to obtain early PICU urines; accepted by nurse staff
The PICU-wide urine collection protocol will be used for future studies
Simple PICU-wide urine collection protocol for nurses Focus on urine collection without nurse screening work; all patients; PICU staff not confused by the protocol
The PICU-wide urine collection protocol will be used for future studies. There were no significant differences in patient characteristics between subjects who did and who did not have a PICU day 1 urine specimen available (not shown). On different PICU days, up to 14% of SCr measurements were performed using leftover samples from other blood tests performed by the clinical team. Figure 2A shows that patients who developed AKI SCr during PICU admission had higher PICU day 1-3 biomarker concentrations than non-AKI SCr patients (statistically significant [p < 0.05] for PICU days 2 and 3 NGAL, day 1 IL-18, day 2 LFABP; Fig. 2A ). Figure 2B shows that there was no significant difference in biomarker concentrations between subjects with and without AKI SCr+UO on PICU days 1-3.
Biomarkers Excretion From PICU Days 1-3 by AKI Status
Biomarkers From PICU Days 1-3 for Predicting AKI Development Table 3 shows the AUCs for biomarkers to predict AKI, when measured on PICU days 1, 2, and 3 if AKI had not yet occurred. Results differed by biomarker and PICU day. Of note, on PICU days 2 and 3, only 2-3 AKI SCr subjects were available for analysis. On PICU day 1, IL-18 predicted AKI with AUC 0.82 (detailed, Table 3 ); NGAL and LFABP predicted AKI with AUCs less than 0.7 (Table 3) . AKI SCr+UO prediction was poor for all 3 PICU day 1 biomarkers (AUC, 0.43-0.65, Table 3 ). For NGAL and LFABP, AKI SCr prediction was substantially higher when measured on PICU days 2 or 3 (e.g., AUC, 0.9 for day 2 NGAL; AUC, 0.77 for day 2 LFABP). A similar phenomenon was seen (i.e., better performance of biomarkers) for predicting AKI SCr+UO when measured on PICU days 2 or 3, versus day 1 (Table 3) .
Biomarker Associations With Prolonged AKI
Thirteen subjects had biomarkers available on the first day of AKI SCr attainment (day 1 AKI SCr ); 7 (54%) had AKI SCr duration 48 hours or more. Biomarker concentrations from day 1 AKI SCr were higher in patients with AKI SCr duration 48 hours or more (statistically significant for LFABP, Fig. 3A) . IL-18 and LFABP predicted AKI SCr 48 hours or more (AUCs, 0.74 and 0.83, respectively), whereas AUC for NGAL was 0.69 (detailed, Fig. 3A) . Fourteen of 33 subjects with AKI SCr+UO (and biomarkers available on day 1 AKI SCr+UO ) had AKI SCr+UO duration 48 hours or more. Figure 3B shows that biomarkers were overall higher in subjects with prolonged AKI SCr+UO , but AUCs for predicting prolonged AKI SCr+UO were lower than AUCs for predicting prolonged AKI SCr (Fig. 3B) .
DISCUSSION
This is one of the first multicenter studies evaluating AKI biomarkers in noncardiac PICU children. A urine collection protocol to obtain early PICU admission urine with deferred consent was feasible. Ability of biomarkers to predict AKI was highly variable and modest.
The fact that AKI occurs early in PICU complicates biomarker research. To measure biomarkers during the short therapeutic AKI window (before SCr rise), collecting urine in the first 1-3 PICU days is critical but not easy. This problem may explain the paucity of PICU AKI biomarker studies. We proposed a protocol-based urine collection, with later eligibility screening, to maximize recruitment in AKI biomarker studies. Barriers often related to differences in site practice (Table 1) . Facilitators generally related to open communication and clear, labor-minimizing actions (e.g., prelabeled tubes). Deferred consent has mainly been limited to studies involving time-sensitive, life-threatening treatments (25); we propose that to move PICU-AKI research forward, deferred consent may help obtain needed specimens in patients most likely to develop AKI. We Figure 2 . Biomarker excretion in the first 3 days of PICU admission by acute kidney injury (AKI) status. Boxplots of urinary neutrophil gelatinaseassociated lipocalin (NGAL), interleukin (IL)-18, and liver fatty acid binding protein (LFABP) on days 1, 2, and 3 of PICU admission, only including subjects with biomarkers available on all three PICU days. Left side of both graphs is biomarkers in subjects without AKI; on the right side of graphs is subjects who developed AKI. A, AKI defined using the serum creatinine criteria (SCr). B, AKI defined using both SCr or urine output criteria. *Statistically significant difference in biomarker concentration between AKI and non-AKI on that PICU day (*p < 0.05; **p < 0.005). AKI SCr = AKI defined using serum creatinine criteria; AKI SCr+UO = AKI SCr or urine output criteria; creat = urine creatinine.
demonstrate such a study is feasible and provide insights on successful performance, at least in the Canadian setting. Despite our protocol, however, several patients were excluded from analysis due to early AKI occurrence and/ or lacking specimens. Of note, we obtained ethics approval for deferred consent, only by not handling urine in any way before obtaining consent. Although biomarkers have been shown to be stable under conditions of our study (26) , urine would ideally be processed immediately, before deferred consent occurs. This may be feasible in other settings or countries.
We investigated the impact of UO AKI criteria on biomarker performance. We confirmed previous pediatric studies showing discrepancy between SCr-and UO-defined AKI (3, 24) , as shown by a substantial number of patients with AKI by one method, but not the other (Supplemental Table 1 , Supplemental Digital Content 2, http://links.lww.com/PCC/A442). Although adult data suggest that UO-defined AKI is associated with clinical outcomes (5, 32) , little is known on this matter in children. UO criteria are challenging to collect, particularly in patients without urinary catheters. Biomarker performance was worse when including UO criteria. It is possible that a small, temporary UO reduction (i.e., stage 1) may not reflect tubular injury, but rather be a sensitive indicator of temporary volume depletion. It may be that in children, more severe UO reductions are more relevant, in terms of outcome associations or renal tissue injury. These UO criteria were based on AKI definition empirically derived for adults. A pediatric-specific, outcome-based UO definition is needed.
There are little data on biomarkers in noncardiac surgery patients. Early PICU biomarker diagnostic performance was highly variable. On PICU day 1, where the sample size was highest, IL-18 was the best predictor of AKI SCr development (AUC, 0.82), comparable to or better than what was previously reported in cardiac and noncardiac PICU patients (12, 13, 16) ; PICU day 1 NGAL AKI SCr prediction was moderate and LFABP performed poorly, unlike some previous reports (12, 15, 17) . There is high diagnostic heterogeneity in the PICU, increasing the likelihood of variability in biomarker performance. Different biomarkers may perform variably by primary disease etiology. For instance, NGAL and IL-18 were shown to be higher in sepsis, possibly because IL-18 is a cytokine and NGAL is neutrophil derived (16, 17) . In those studies, NGAL predicted AKI in sepsis, but IL-18 was only diagnostic of AKI without sepsis. Biomarkers appear to be higher in younger children (12) , possibly due to tubular immaturity. Biomarkers have also been shown to predict more severe (e.g., stage 2) AKI better than stage 1 AKI (12). It is likely that there is more AKI misclassification in stage 1 AKI (i.e., patients without renal injury, but only reduced GFR due to temporary volume depletion). Our sample size precluded analysis of diagnostic, age, or AKI severity subgroups. Future studies should be powered to evaluate other factors potentially affecting biomarkers and (12, 15) . Future studies should evaluate the extent to which adding biomarkers to clinical prediction models significantly improves prediction and ultimately is cost-effective, for future AKI therapeutic trial selection and clinical care. Our sample size was too small to make strong conclusions on biomarker performance from PICU days 2 or 3. However, AKI prediction was much stronger for NGAL and LFABP on these days. It is possible that after the initial high acuity resuscitation phase, other factors affecting biomarker concentrations (e.g., inflammation, fluid administration) are less prominent after day 1. Early PICU biomarker excretion patterns may be distinct for different biomarkers. Future larger studies should elucidate the extent to which timing of biomarker measurement may impact diagnostic performance (as has been shown in cardiac surgery patients).
LFABP and less so, IL-18, predicted AKI duration more than 48 hours, supporting this previously shown utility of biomarkers (17) . When SCr rises, there is often uncertainty on whether there is mild, temporary SCr rise virus an early sign of significant AKI (i.e., true cell injury). Biomarkers may identify tissue injury and help make timely decisions on nephrotoxins and fluid management. We used AKI more than 48 hours to represent prolonged AKI, based previous studies. Future studies may identify alternative "AKI duration" thresholds.
Study limitations included low sample size (described above) and multiple testing. Baseline SCr was missing for ~50% patients and had to be estimated, which may have resulted in AKI misclassification. Lack of baseline SCr in PICU patients is common, highlighting an inherent issue with SCr-based AKI definitions. We did not collect detailed UO criteria after PICU day 7, based on our previously research. Though it is conceivable that some patients may have developed UO-defined AKI later, this proportion would unlikely be high enough to substantially affect results and also, biomarkers may not be useful to predict such delayed UO-AKI.
CONCLUSION
Validating early AKI biomarkers may improve AKI management and trial performance. Better characterization of biomarker performance (timing, subgroups) and more discovery research to identify valid AKI biomarkers in the PICU are needed. An early PICU urine collection protocol, likely critical for PICU AKI biomarker studies, is feasible and beneficial for obtaining early PICU urine specimens. Figure 3 . Association of biomarkers from the first day of acute kidney injury (AKI) attainment with AKI duration at least 48 hr. Boxplots of biomarker concentrations (y-axis) measured on the first PICU day the patient fulfilled criteria for AKI, in subjects with AKI duration (fulfilling criteria for AKI) less than versus greater than or equal to 48 hr (indicated on x-axis). Within graph statistics shown are the p value for biomarker concentration differences between the two groups (Mann-Whitney U test) and the area under the receiver operating characteristic curve (AUC) for each biomarker to predict AKI duration at least 48 hr (with lower and upper 95% CI). A, AKI defined using serum creatinine criteria (AKI SCr ). B, AKI defined using both serum creatinine or urine output criteria (AKI SCr+UO ). IL-18 = interleukin-18, LFABP = liver fatty acid binding protein, NGAL = neutrophil gelatinase-associated lipocalin.
